J&J To Record Nearly $700 Million Charge Over Abandoned Antiviral Drug Program.

Reuters (3/21, Joseph) reports that Thursday, Johnson & Johnson “said it will record a nearly $700 million impairment charge in the first quarter of 2019 related to the abandoned development of its experimental antiviral drug, AL-8176,” which was in devel...